GlassScriptPhysician profile
Renuka Dulala
NPI 1861652240
$845.28
in general payments reported to CMS, 2019-2025
19 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.68 · 2020: $15.32 · 2021: $85.37 · 2022: $89.61 · 2023: $202 · 2024: $181 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $560.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $154.73 | 2023-2025 | Rybrevant, Imbruvica, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $141.34 | 2019-2025 | Opdivo |
| Astellas Pharma US INC | $77.10 | 2023-2024 | Padcev |
| Merck Sharp & Dohme LLC | $51.97 | 2019-2023 | Keytruda |
| Celgene Corporation | $49.91 | 2022-2024 | Reblozyl |
| Abbvie INC. | $48.27 | 2024-2025 | |
| Array Biopharma INC | $44.67 | 2023-2025 | Mektovi, Braftovi, Tukysa |
| Pfizer INC. | $40.28 | 2023 | |
| Amgen INC. | $39.75 | 2021-2023 | Lumakras |
| Incyte Corporation | $27.14 | 2025 | Jakafi |
| Novartis Pharmaceuticals Corporation | $27.07 | 2024 | |
| Servier Pharmaceuticals LLC | $21.22 | 2023 | |
| Genzyme Corporation | $20.90 | 2021 | |
| Foundation Medicine, INC. | $20.60 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $19.29 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $16.32 | 2019 | |
| Blue Earth Diagnostics | $16.27 | 2024 | |
| Myriad Genetic Laboratories, INC. | $15.16 | 2021 | |
| Seagen INC. | $13.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renuka Dulala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.